Advances in Dyslipidemia: What Have We Learned From ACC 2017

PCSK9 Inhibitors – Leading Up to Recent Outcomes Data

Intensive vs Standard Statin Therapy

GLAGOV Effect of PCSK9 Inhibitors on CHD Progression

IVUS Trials How Low Is Too Low When Lowering LDL-C?

Guidelines to Manage Dyslipidemia

SPIRE: Bococizumab CV Outcomes

FOURIER: Cardiovascular Outcomes With PCSK9 Inhibition

FOURIER Trial Design

FOURIER: LDL-C Reduction

FOURIER: CV Outcomes

FOURIER: Lower LDL-C Is Better

Clinical Implications of FOURIER

Safety of PCSK9 Monoclonal Antibodies

FOURIER: Safety

EBBINGHAUS Cognitive Study of Patients Enrolled in FOURIER Trial: Endpoints

Primary Endpoint Spatial Working Memory Strategy Index

Cognitive Assessments by Achieved LDL-C and Treatment

IMPROVE-IT Long-Term Efficacy and Safety

Abbreviations

Abbreviations (cont)